Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

Core Viewpoint - Savara Inc. has amended its loan and security agreement with Hercules Capital, enhancing its financial position and liquidity [1] Financial Strengthening - The amended loan agreement allows for an additional $75 million to be available upon FDA approval of MOLBREEVI, Savara's investigational therapy for autoimmune pulmonary diseases [1]